Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientific Society of Infectious Disease S... by V. T. Ivashkin, V. P. Chulanov, N. A. Mamonova, M. V. Maevskaya, M. S. Zharkova, I. N. Tikhonov, P. O. Bogomolov, E. V. Volchkova, A. S. Dmitriev, O. O. Znojko, E. A. Klimova, K. V. Kozlov, I. E. Kravchenko, E. Yu. Malinnikova, R. V. Maslennikov, M. I. Mikhailov, K. E. Novak, I. G. Nikitin, V. E. Syutkin, E. V. Esaulenko, A. A. Sheptulin, E. N. Shirokova, N. D. Yushchuk

“…The spectrum of their effectiveness allows to achieve a sustained virological response in more than 90 % of cases, even in groups that were not previously considered even as candidates for therapy or were difficult to treat — patients receiving renal replacement therapy, after liver transplantation (or other organs), at the stage of decompensated liver cirrhosis, HIV co-infected, etc. Interferons are excluded from the recommendations due to their low effectiveness and a wide range of adverse events. …”
Get full text

Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease by Hiam Naiditch, Michael R. Betts, H. Benjamin Larman, Moshe Levi, Avi Z. Rosenberg

“…Delayed transcription of Type I and Type III interferons by SARS-CoV-2 may lead to early disinhibition of viral replication. …”
Get full text